OXIS International, Inc. Announces The Introduction Of Breakthrough New Ergothioneine-Based Supplements For Joint Health And Healthy Aging
Main Category: Bones / OrthopedicsAlso Included In: Arthritis / Rheumatology; Seniors / Aging
Article Date: 25 Aug 2010 - 4:00 PDT
| Patient / Public: | ![]() |
2 (2 votes) |
| Healthcare Prof: | ![]() |
OXIS INTERNATIONAL, INC. (OTC Bulletin Board: OXIS, Paris: OXI) is proud to announce that it will introduce the benefits of Ergothioneine to the consumer market in September 2010 via breakthrough products for joint health and healthy aging. The first products, ErgoFlex® and ErgoPlex®, will initially be marketed via a direct mail offering being developed in partnership with Creative Direct Marketing Group, the leading service provider in the direct mail sector of the direct to consumer channel.
"These exciting new formulas provide a previously unavailable suite of benefits to the growing number of baby boomers and younger active lifestyle consumers seeking better solutions to combat the effects of aging in general and more specifically, joint pain," stated Bernie Landes, President of Oxis. "These products provide a unique blend of Ergothioneine and complementary and synergistic ingredients that treat aging and joint health as multidimensional complexes," he added. "By taking advantage of the unique functional benefits of Ergothioneine alone and as a co-factor with other key nutraceutical compounds, we believe that Oxis will be able to provide highly beneficial, proprietary solutions unavailable from any other products in the market today," Landes concluded.
With the introduction of these products, Oxis will stand alone as a supplier of Ergothioneine based products to the global market. These initial products are part of a broad strategy to develop the growing market opportunities for proprietary new approaches to dietary supplement, functional food and beverage and personal care products.
Forward-Looking Statement
This press release contains forward-looking statements that involve numerous risks and uncertainties. Actual results, performance or achievements could differ materially from those anticipated in such forward-looking statements as a result of certain factors, including those set forth in the Company's filings with the Securities and Exchange Commission.
Source: OXIS International, Inc
Visit our bones / orthopedics section for the latest news on this subject.
MLA
12 Feb. 2012. <http://www.medicalnewstoday.com/releases/198834.php>
APA
http://www.medicalnewstoday.com/releases/198834.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




